David Danziger Acquires 10,000 Shares of ALT5 Sigma (NASDAQ:ALTS) Stock

ALT5 Sigma Corporation (NASDAQ:ALTS) Director David Danziger acquired 10,000 shares of the firm’s stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $7.30 per share, for a total transaction of $73,000.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at approximately $146,000. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

ALT5 Sigma Stock Down 9.0%

Shares of NASDAQ ALTS opened at $2.63 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 1.45. The stock’s fifty day moving average price is $4.94 and its two-hundred day moving average price is $6.25. ALT5 Sigma Corporation has a one year low of $1.74 and a one year high of $10.95.

Hedge Funds Weigh In On ALT5 Sigma

Hedge funds have recently bought and sold shares of the company. Evernest Financial Advisors LLC bought a new position in ALT5 Sigma in the second quarter valued at approximately $87,000. Bridgeway Capital Management LLC boosted its holdings in shares of ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after purchasing an additional 1,661 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ALT5 Sigma in the 2nd quarter valued at $380,000. Finally, Geode Capital Management LLC increased its stake in shares of ALT5 Sigma by 27.6% in the 2nd quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after purchasing an additional 42,157 shares during the last quarter. 6.27% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALTS. Weiss Ratings restated a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Wednesday. Wall Street Zen downgraded ALT5 Sigma from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.